| 王瑾,张延顺,王勇,等.阿帕替尼在晚期肿瘤中的疗效及安全性分析[J].中国临床保健杂志,2019,22(4):556-558. |
| 阿帕替尼在晚期肿瘤中的疗效及安全性分析 |
| Efficacy and safety of apatinib in advanced tumors |
| 投稿时间：2018-09-12 |
| DOI：10.3969/J.issn.1672-6790.2019.04.033 |
| 中文关键词: 肿瘤 药物疗法 血管生成抑制剂 治疗结果 |
| 英文关键词: Neoplasms Drug therapy Angiogenesis inhibitors Treatment outcome 〖FL |
| 基金项目: |
|
| 摘要点击次数: 6037 |
| 全文下载次数: 6043 |
| 中文摘要: |
| 目的 探讨阿帕替尼在晚期肿瘤中的疗效及安全性。 方法 对30例恶性肿瘤Ⅳ期患者使用阿帕替尼±化疗,观察疗效、不良反应,并予以临床随访,观察患者的无进展生存期。 结果 在30例患者中,部分缓解患者4例,稳定15例,疾病控制率:63.3%,进展7例。1例患者因Ⅳ度不良反应停药,随访发现部分缓解+稳定组较进展组具有生存优势,两组之间差异有统计学意义(P=0.039)。COX分析显示:性别、年龄、美国东部肿瘤协作组(ECOG)评分、高血压、乏力、手足反应均不是影响患者无进展生存期的预后因素(P＞0.05)。 结论阿帕替尼在晚期肿瘤中具有一定的疗效,并且在临床使用中也较为安全。 |
| 英文摘要: |
| Objective To investigate the efficacy and safety of apatinib in the treatment of advanced tumors. Method Apatinib plus or not chemotherapy plus or not were used in 30 patients with malignant tumor Ⅳ stage.Their curative effect,adverse reaction,and clinical follow-up,the PFS were observed. Results Among 30 patients,there were 4 PR patients,15 SD patients,DCR:63.3%,and PD7 patients.One patient stoped drug withdrawal because of Ⅳ degree adverse reactions.The follow-up found that PR+SD group had a survival advantage in the PD group,statistically significant difference between the two groups (P=0.039).COX analysis showed that gender,age,ECOG score,hypertension,fatigue and hand-foot reaction were not prognostic factors affecting the progressionless survival of patients (P>0.05). Conclusion Apatinib is effective and safe in the treatment of advanced tumors. |
|
查看全文
|
| 关闭 |
|
|
|